{"name":"Anavex Life Sciences","slug":"anavex","ticker":"AVXL","exchange":"NASDAQ","domain":"anavex.com","description":"Anavex Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative treatments for neurodegenerative diseases. The company's lead product candidate, ANAVEX2-73, is being developed for the treatment of Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. Anavex has a strong pipeline of preclinical and clinical-stage programs, and its products have shown promising results in early-stage clinical trials.","hq":"New York, NY","founded":0,"employees":"","ceo":"Christopher U. Missling","sector":"Clinical-Stage Neuroscience Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$520M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":37592000,"netIncome":-46377000,"cash":102577000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2038-06-01","label":"ANAVEX2-73 patent cliff ($0.00 at risk)","drug":"ANAVEX2-73","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"ANAVEX2-73","genericName":"ANAVEX2-73","slug":"anavex2-73","indication":"Alzheimer's disease","status":"phase_3"},{"name":"ANAVEX2-73 Intravenous","genericName":"ANAVEX2-73 Intravenous","slug":"anavex2-73-intravenous","indication":"Alzheimer's disease","status":"phase_2"},{"name":"ANAVEX2-73 oral liquid","genericName":"ANAVEX2-73 oral liquid","slug":"anavex2-73-oral-liquid","indication":"Alzheimer's disease","status":"phase_2"},{"name":"ANAVEX3-71 oral capsules","genericName":"ANAVEX3-71 oral capsules","slug":"anavex3-71-oral-capsules","indication":"Alzheimer's disease","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ANAVEX3-71","genericName":"ANAVEX3-71","slug":"anavex3-71","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ANAVEX2-73","genericName":"ANAVEX2-73","slug":"anavex2-73","phase":"phase_3","mechanism":"ANAVEX2-73 is a sigma-1 receptor agonist that activates neuroprotective pathways to treat neurodegenerative diseases.","indications":["Alzheimer's disease","Parkinson's disease dementia"],"catalyst":""},{"name":"ANAVEX2-73 Intravenous","genericName":"ANAVEX2-73 Intravenous","slug":"anavex2-73-intravenous","phase":"phase_2","mechanism":"ANAVEX2-73 is a small molecule that modulates sigma-1 receptors and muscarinic acetylcholine receptors, which may have neuroprotective effects.","indications":["Alzheimer's disease","Parkinson's disease"],"catalyst":""},{"name":"ANAVEX2-73 oral liquid","genericName":"ANAVEX2-73 oral liquid","slug":"anavex2-73-oral-liquid","phase":"phase_2","mechanism":"ANAVEX2-73 is an oral liquid formulation of a sigma-1 receptor agonist.","indications":["Alzheimer's disease","Parkinson's disease"],"catalyst":""},{"name":"ANAVEX3-71","genericName":"ANAVEX3-71","slug":"anavex3-71","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ANAVEX3-71 oral capsules","genericName":"ANAVEX3-71 oral capsules","slug":"anavex3-71-oral-capsules","phase":"phase_2","mechanism":"ANAVEX3-71 is a sigma-1 receptor agonist that modulates neuroprotective and neuroinflammatory pathways in the central nervous system.","indications":["Alzheimer's disease","Parkinson's disease"],"catalyst":""}],"recentEvents":[{"date":"2023-02-22","type":"regulatory","headline":"Anavex Life Sciences Receives Orphan Drug Designation for ANAVEX2-73 for the Treatment of Parkinson's Disease","summary":"Anavex Life Sciences announced that the U.S. FDA has granted Orphan Drug Designation to ANAVEX2-73 for the treatment of Parkinson's disease.","drugName":"ANAVEX2-73","sentiment":"positive"},{"date":"2022-11-14","type":"earnings","headline":"Anavex Life Sciences Reports Third Quarter 2022 Financial Results","summary":"Anavex Life Sciences reported its financial results for the third quarter of 2022, with a net loss of $4.4 million.","drugName":"","sentiment":"neutral"},{"date":"2022-08-01","type":"deal","headline":"Anavex Life Sciences Enters into Licensing Agreement with a Global Pharmaceutical Company","summary":"Anavex Life Sciences announced that it has entered into a licensing agreement with a global pharmaceutical company for the development and commercialization of ANAVEX2-73.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-09","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2026-02-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxPcGRqQXpkVk1IaGlkS3A1eHo2TUVKakFJVWRwNEFnODlwQUd4QXJIQ1FxOEVudTFyUktjbkFtR2JNaVhacDZXRUw5b2Y1V3RMb1ZRTHNpblI2TWk3NWlmWE80cnc1aHppdXZQMlpBM0JUaWJieWtkanMzX3dzN1VnMVRyZnpIdFFpRy0zMkwzX1hvQXdXNUxXdE9IT3Z0RlAzRVU3SmdROE1KUGhPc3Nhay1Vc09idjIxcExxZndEc3RNZ1o2TGhBTm5PNTQ4YTA4VVhmRFl3LUt3MEVvZkFOd1NGLVNfODgtYU93RU13cWJfUQ?oc=5","date":"2025-12-12","type":"regulatory","source":"TechStock²","summary":"Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025) - TechStock²","headline":"Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, an","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQYkpTZThQdWRyMDhpUm5nVzhVY2pmTTFKUkQyR1lFRjNMQXZCZnFzbVhLZG1FNVNjc1BIWkJLSlZPNHFOOFRtX1ZsT0xuS29VQXJweTJ0RU9kUFh6STUwVHJ3cGJNdDdmNkVCUFA5U1F0bEJKQ3BFaWJXazVxYjJmTVdlUVJ1RG5EOEpLTjBJSUdnOE14STNfcFM4RUhHZjBlQl9PYm9aSk9COGJaY2stMVpkS3o0UUVMUkNqdnQ2Mmg5MUk?oc=5","date":"2025-12-02","type":"regulatory","source":"Seeking Alpha","summary":"Anavex Life Sciences: Negative CHMP Decision Does Not Bode Well For Future Approval For Alzheimer's - Seeking Alpha","headline":"Anavex Life Sciences: Negative CHMP Decision Does Not Bode Well For Future Approval For Alzheimer's","sentiment":"positive"},{"date":"2025-11-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2025-11-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-16","type":"regulatory","source":"simplywall.st","summary":"Why Anavex Life Sciences (AVXL) Is Down After an EMA Setback for Its Alzheimer’s Drug Application - simplywall.st","headline":"Why Anavex Life Sciences (AVXL) Is Down After an EMA Setback for Its Alzheimer’s Drug Application","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-15","type":"regulatory","source":"simplywall.st","summary":"Anavex Life Sciences (AVXL): Valuation Review Following EMA Setback for Lead Alzheimer’s Drug - simplywall.st","headline":"Anavex Life Sciences (AVXL): Valuation Review Following EMA Setback for Lead Alzheimer’s Drug","sentiment":"neutral"},{"date":"2025-11-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPa3FCYnB6ZlV1cmUzQTctTUtjMUh5NmhnZ291Ylc4Q3JGUW1GVW1oYkJiYUdScmIzenN1ck9iRVZ5Y1ktbE9xVVoyWkQwTTlCa3lGYUVmZG5KdXp6WlVWTEtUcTE5TG5GMGZNRmVqMS1lQ3RmbGowbFF2OTM5N01mSHF1elF6NlZmN1NuMkQ2cFRQVmZqQUFxSWxvdVdNRDkyN1NoM2RRaC1oeEZ6RUYtREFEMTh6ZjY5Y3FaMW53?oc=5","date":"2025-11-13","type":"pipeline","source":"GuruFocus","summary":"Anavex Life Sciences (AVXL) Shares Dip Amid Short Call by Martin Shkreli - GuruFocus","headline":"Anavex Life Sciences (AVXL) Shares Dip Amid Short Call by Martin Shkreli","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNNTJOVTRwSk15WXhRNXhDTDVBVk9pWUZwWDZJNWRtVzJqT21ycDR4aWFtUGZMNHNkUF82NTlOUDVrTGpkX1Q3akswVmxmYTJDWmJ5dkhsUE1wbVFLX3ZpYzZkem5qNmloWmdiSGFrQ0s4aVhtZUROTUpaT2dFM0NFZFZkcHhPQmxTanRTeHd4c2M5WERTdVNMMS1yRFkyM1cyNkNnU1hWX21oSzlMR3g4enY5aGpacWllU0JzQmJsTQ?oc=5","date":"2025-11-12","type":"pipeline","source":"Seeking Alpha","summary":"Anavex Nears Alzheimer's Decision With Limited Pipeline Offsets And ATM Overhang (AVXL) - Seeking Alpha","headline":"Anavex Nears Alzheimer's Decision With Limited Pipeline Offsets And ATM Overhang (AVXL)","sentiment":"neutral"},{"date":"2025-08-12","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-07-28","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[{"drugName":"ANAVEX2-73","drugSlug":"blarcamesine","patentNumber":"","type":"Patent Cliff","expiryDate":"2038-06-01","territory":"US","annualRevenue":0}],"drugCount":5,"phaseCounts":{"phase_3":1,"phase_2":3,"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Roche Holding","Eli Lilly and Company"],"therapeuticFocus":["Alzheimer's disease","Parkinson's disease"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":37592000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-46377000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":102577000,"cashHistory":[],"totalAssets":103815000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}